Biaxin XL Unlikely To Face Generic Competition In Near-Term Following Preliminary Injunctions
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy says it will seek to amend its ANDA for a 500 mg dose to carve out labeling language that may be protected by an Abbott patent.
You may also be interested in...
Teva's Biaxin XL Generic Would Irreparably Harm Abbott, Court Rules
Teva is preliminarily enjoined from launching extended-release clarithromycin pending a ruling on the merits of patent infringement claims. A Chicago federal judge preliminarily rules that only one of three Abbott patents at issue is valid. Teva expects to file an expedited appeal to the Federal Circuit.
NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue
FDA’s Arcoxia Decision Offers New Evidence Of Conservative Review Stance
FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency